NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema, HAE. NTLA-2002 is a wholly owned investigational in vivo CRISPR ...

The latter involved NTLA-2002. This treatment addresses hereditary angioedema (HAE). It’s a genetic condition that causes severe swelling. The Street reacted to those test results by knocking 20 ...

Intellia is developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE). In the past year, shares of Intellia have plunged 57.3% compared with the industry ...

The company revealed that they are going to direct efforts toward their late-stage programs, including NTLA-2002. In addition, the company proclaimed that this change in direction would involve ...

emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively. Intellia ...